Daiwa Securities Group
TRVI icon

Daiwa Securities Group’s Trevi Therapeutics TRVI Stock Holding History

Daiwa Securities Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-427
Closed -$5K – 1428
2025
Q4 		$5K Buy
427
+122
+40% +$1.41K ﹤0.01% 1241
2025
Q3 		$3K Hold
305
– – ﹤0.01% 1253
2025
Q2 		$2K Hold
305
– – ﹤0.01% 1232
2025
Q1 		$2K Buy
+305
New +$1.46K ﹤0.01% 1200

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Daiwa Securities Group's TRVI Position: Q1 2026 in Review

Daiwa Securities Group sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 427 shares — an estimated $5K sold.

Daiwa Securities Group first reported a position in TRVI in Q1 2025 and held it in 4 quarters. The position peaked at $5K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Daiwa Securities Group reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 427 Trevi Therapeutics shares in Q1 2026, an estimated $5K.
  • Daiwa Securities Group first reported a position in Trevi Therapeutics in Q1 2025 and held it in 4 quarters.
  • Daiwa Securities Group's Trevi Therapeutics position peaked at $5K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.